HeartBeam Study Shows Portable ECG Device Can Help Identify Heart Attack Risk
A peer-reviewed study published in JACC: Advances demonstrates that HeartBeam's credit card-sized ECG device, combined with a risk prediction algorithm, can accurately identify heart attack risk in patients with chest pain, potentially enabling earlier detection and treatment.
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study, which evaluated 184 patients, found that the algorithm achieved an “area under the curve” (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. The AUC rose to 92.9% when a personal, symptom-free baseline ECG was available for comparison.
The results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement. The full press release is available at https://ibn.fm/ainxV.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.
The implications of this study are significant. Chest pain is one of the most common reasons for emergency department visits, and rapid, accurate assessment of heart attack risk is critical. The HeartBeam device, being credit card-sized and portable, could enable earlier detection in settings where traditional ECG equipment is not available, such as in ambulances, primary care offices, or even at home. The high AUC values suggest that the algorithm is highly accurate, particularly when a baseline ECG is available, which could reduce unnecessary hospital admissions and allow for more efficient use of healthcare resources.
Furthermore, the ability to compare a current reading with a personal baseline could help differentiate between acute changes and chronic abnormalities, potentially reducing false alarms. As the company advances its clinical program, this technology could become a standard tool for heart attack risk assessment, ultimately improving patient outcomes. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.